Cancer Immunology, Immunotherapy

, Volume 57, Issue 9, pp 1279–1289

Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain

  • Robert M. Prins
  • Chengyi J. Shu
  • Caius G. Radu
  • Dan D. Vo
  • Haumith Khan-Farooqi
  • Horacio Soto
  • Meng-Yin Yang
  • Muh-Shi Lin
  • Stephanie Shelly
  • Owen N. Witte
  • Antoni Ribas
  • Linda M. Liau
Original Article

Abstract

It is commonly believed that T cells have difficulty reaching tumors located in the brain due to the presumed “immune privilege” of the central nervous system (CNS). Therefore, we studied the biodistribution and anti-tumor activity of adoptively transferred T cells specific for an endogenous tumor-associated antigen (TAA), gp100, expressed by tumors implanted in the brain. Mice with pre-established intracranial (i.c.) tumors underwent total body irradiation (TBI) to induce transient lymphopenia, followed by the adoptive transfer of gp10025–33-specific CD8+ T cells (Pmel-1). Pmel-1 cells were transduced to express the bioluminescent imaging (BLI) gene luciferase. Following adoptive transfer, recipient mice were vaccinated with hgp10025–33 peptide-pulsed dendritic cells (hgp10025–33/DC) and systemic interleukin 2 (IL-2). This treatment regimen resulted in significant reduction in tumor size and extended survival. Imaging of T cell trafficking demonstrated early accumulation of transduced T cells in lymph nodes draining the hgp10025–33/DC vaccination sites, the spleen and the cervical lymph nodes draining the CNS tumor. Subsequently, transduced T cells accumulated in the bone marrow and brain tumor. BLI could also detect significant differences in the expansion of gp100-specific CD8+ T cells in the treatment group compared with mice that did not receive either DC vaccination or IL-2. These differences in BLI correlated with the differences seen both in survival and tumor infiltrating lymphocytes (TIL). These studies demonstrate that peripheral tolerance to endogenous TAA can be overcome to treat tumors in the brain and suggest a novel trafficking paradigm for the homing of tumor-specific T cells that target CNS tumors.

Keywords

Brain tumor Immunotherapy T cell trafficking Dendritic cells 

Abbreviations

BLI

Bioluminescent imaging

CNS

Central nervous system

DC

Dendritic cell

TAA

Tumor-associated antigen

i.c.

Intracranial

TBI

Total body irradiation

TIL

Tumor-infiltrating lymphocytes

Supplementary material

262_2008_461_MOESM1_ESM.ppt (40 kb)
Supplementary Figure 1 (PPT 41 kb)

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Robert M. Prins
    • 1
    • 2
    • 3
    • 4
  • Chengyi J. Shu
    • 5
  • Caius G. Radu
    • 3
    • 5
  • Dan D. Vo
    • 6
  • Haumith Khan-Farooqi
    • 1
  • Horacio Soto
    • 1
  • Meng-Yin Yang
    • 1
  • Muh-Shi Lin
    • 1
  • Stephanie Shelly
    • 5
  • Owen N. Witte
    • 2
    • 3
    • 5
    • 7
  • Antoni Ribas
    • 3
    • 6
    • 8
  • Linda M. Liau
    • 1
    • 3
    • 4
  1. 1.Department of Surgery, Division of NeurosurgeryDavid Geffen School of Medicine at UCLALos AngelesUSA
  2. 2.Department of Microbiology, Immunology and Molecular GeneticsDavid Geffen School of Medicine at UCLALos AngelesUSA
  3. 3.Jonsson Comprehensive Cancer CenterDavid Geffen School of Medicine at UCLALos AngelesUSA
  4. 4.Brain Research InstituteDavid Geffen School of Medicine at UCLALos AngelesUSA
  5. 5.Department of Molecular and Medical PharmacologyDavid Geffen School of Medicine at UCLALos AngelesUSA
  6. 6.Department of Surgery, Division of Surgical OncologyDavid Geffen School of Medicine at UCLALos AngelesUSA
  7. 7.Howard Hughes Medical InstituteDavid Geffen School of Medicine at UCLALos AngelesUSA
  8. 8.Department of Medicine, Division of Hematology-OncologyDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations